PPT-Supplemental Figure S1 Supplemental

Figure S1 A Schematic shows the three KREN1 KREN2 and KREN3 20S editosomes and their protein interactions identified by yeast twohybrid and coexpression studies dashed lines Schnaufer et al 2003 Schnaufer et al 2010 Mehta et al 2015 BD Networks show detailed editosome architecture revealed by crosslinking and mass spectrometry CXMS McDermott et al 2016 Network edge widths are proportional to the number of interlinks observed between two proteins All previously described interactions between editosome proteins were found in our crosslinking data . 2012). 345,641 diverse . protein . families. Multiple. sequences. 2. 47. ,. 437. with . at least . 3. homologous. . sequences. Full length. proteins. 224. ,4. 09. . where majority of sequences have . Supplemental Figure 1 Supplemental Figure 2 Supplemental Figure 3 Supplemental Figure 4 Supplemental Table 1 Supplemental Figure 5 CD44. GM130. CD40. MSCs. EVs. B. C. Supplemental Figure 1. Supplemental Figure 2. Supplemental Figure 3 . Supplemental Figure 4. A. B. A. B. C. Supplemental Figure 5. D. SSC. CD206. CD206. 25.7%. 14%. DMSs . and dietary intake and lifestyle factors at . exam 5 . for . all participants (n=1880). . -log10 (P value). 60. 50. 40. 30. 20. 10. 132 Nutrients/Bioactive . 129 Food group1 (FFD). 29 Food group2 (FG5Serv). fpkm. ). PD-L1 (. fpkm. ). CD8 (. fpkm. ). Iba1 (. fpkm. ). p. < 0.001. p. < 0.001. p. < 0.001. p. < 0.001. GM-CSF. GM-CSF. GM-CSF. GM-CSF. Supplemental Figure 1. Gene expression analysis in breast cancer cases from TCGA database. Gene expression levels of CD8, Iba1, PD-L1, and PD-L2 in breast cancer were compared between the cases with and without GM-CSF expression. The Mann-Whitney . 1. 5. 10. 30. 50. 100. SP600125. 0,1. 1. 2. 5. 10. 20. ER-27319. 1. 5. 10. 30. 50. 100. Inhibitors concentration (µM). A. B. Supplemental Figure 1: B cell survival (A) . B cells were pre-treated with kinase inhibitors (GF109203 (PKC. With first H2 blockers or PPI prescriptions between October, 2006 and September, 2008. First acid suppression therapy prescription was PPI . First acid suppression therapy prescription was H2 Blockers . GSE47460_GPL14550 . GSE47460_GPL6480 . Supplemental Figure 2. Megakaryocyte score. Platelet score. FVC. DLCO. A. B. Megakaryocyte score. Platelet score. FVC. DLCO. r = -0.09331, p = 0.5237. r = 0.07781, p = 0.6721. suboptimally. positioned. There was a normal . cardiothymic. silhouette. The lungs were clear. Air in scattered loops of . nondilated. small and large bowel, within all four quadrants of the abdomen.. Viral infection. Inflammation response. -log10(. p. -value) -log10(. Scale bar: 10nm. 9.5nm. 14.7nm. Average diameter:. A. B. Supplemental figure 2. ELISA using FT and GnH-FT as antigens. A. B. * P <0.05, ** P<0.01, *** P<0.001, and **** P<0.00001. **. *. *. B. Supplemental Figure 2. Tissue. Adrenal gland . Appendix. Appendix . Bone marrow . Breast . Breast cancer. Bronchus Respiratory . Cartilage. Cerebellum . Cerebellum . Cerebellum . Cerebral cortex. Cerebral cortex. children . aged 2–5 years . in Medicaid receiving . clinical care for . attention-deficit/hyperactivity disorder (ADHD): United States, 2011. 0.45-1.40%. 1.41-1.70%. 1.71-2.05%. 2.06-3.38%. SUPPLEMENTAL FIGURE 5. . Top layer. Bottom layer. PDMS rod. +. cells. Nuclei. F-actin. Supplemental Figure 1: Lung Endothelial MPS. A.. B.. Supplemental Figure 1: A) Schematic of lung endothelial MPS. B) Imaging demonstrating coverage with endothelial cells prior to incubation of plasma in the lumens..